Asbestosis is defined as pulmonary parenchymal fibrosis secondary to inhalation of asbestos fibres. The lag between exposure and onset of symptoms is usually 20 years or longer. Histologically, fibrosis is first seen in the interstitium of respiratory bronchioles, particularly in the lower lobes adjacent to the visceral pleura. With advancing disease, the fibrous tissue extends into the adjacent alveolar septa, eventually involving the entire lobule.
In the most severe cases there is diffuse interstitial fibrosis associated with parenchymal remodelling and honey-combing. Asbestos bodies are almost always identifiable microscopically in the fibrous tissue or macrophages in residual air spaces. Early CT changes indicative of asbestosis are the presence of subpleural curvilinear lines and dots, pleural-based nodular irregularities, parenchymal bands and septal lines. The fine reticulation eventually progresses to a coarse linear pattern with honeycombing (Fig. 1). These abnormalities are usually most severe in the subpleural regions of the lower lobes. HRCT–pathological correlation studies have shown that subpleural dots and branching structures correspond to peribronchiolar fibrosis. The sensitivity of HRCT over the chest radiograph for the identification of early fibrosis in asbestos-exposed individuals is well established; however, sensitivity is not 100% and a histopathological diagnosis of asbestosis can be present in patients with normal or near-normal HRCTs. The diagnosis of asbestosis has significant implications for the patient in terms of prognosis, work ability and the possibility of receiving legal compensation. Although both the chest radiograph and HRCT can confirm previous exposure, the diagnosis of asbestosis is largely inferential and based on demonstrating a compatible structural lesion, critically an appropriate exposure history, and the exclusion of other plausible conditions. One of the problems in interpreting the presence of interstitial fibrosis, whether on chest radiography or HRCT, is the fact that asbestos-exposed individuals are as likely as the rest of the population to develop other causes of fibrosis such as IPF.
Distinguishing asbestosis from IPF is also desirable, as asbestosis is associated with a much slower rate of progression and hence a better prognosis. Discrimination between the two by HRCT appearances is usually impossible. However, pleural disease may be a crude discriminator: in Akira et al's study, pleural disease was found in 83% (66/80) of patients with asbestosis but only in 4% (3/80) of patients with IPF. Copley et al found no statistically significant differences in the coarseness of fibrosis between individuals with asbestosis and a cohort of individuals with biopsy-proven UIP, although the CT findings of asbestosis were strikingly different from NSIP; the quality of fibrosis was coarser, there was a lower proportion of ground-glass opacification, and a higher likelihood of a basal and subpleural distribution.
Classic HRCT Findings
• Asbestos-related benign pleural disease consists of either parietal pleural plaques in characteristic locations or diffuse visceral pleural thickening
• The presence of such pleural disease in individuals with HRCT findings compatible with UIP/NSIP pattern suggests the diagnosis of asbestosis in patients with an appropriate exposure history

FIGURE 1 ■ Asbestosis. (A) HRCT features of early asbestosis include subpleural lines (arrowheads) and fine reticulation (arrows). These subtle abnormalities persisted on prone sections. (B) In more advanced disease, a coarse reticular pattern with honeycombing, often indistinguishable from usual interstitial pneumonia on HRCT, is seen in the left lower lobe. Note the calcified pleural plaques in both examples.
责任编辑:admin